Cyproterone Acetate and Risk of Meningioma: A Nationwide Cohort Study

This nationwide cohort study investigated the association between cyproterone acetate (CPA) use and the risk of meningioma in Denmark. The study included individuals born between 1930 and 2000, followed from age 15 or later until 2017. The findings indicated that high cumulative doses of CPA significantly increased the risk of meningioma, with a 6-20 fold higher risk compared to low doses. This led to the European Medicines Agency recommending a restriction of CPA to less than 10 mg per day. The study underscores the importance of monitoring CPA dosage to mitigate the risk of meningioma.